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The implantable cardioverter-defibrillator (LCD) greatly reduces
the incidence of sudden cardiac death among patients with recur
.
rent sustained ventricular tachycardia and fibrillation who do not
respond to conventional antiarrhythmic therapy . A cast.
effectiveness analysis was performed, comparing the LCD, amio-
darone and conventional agents . Actual variable costs of hospital-
ization and follow-up care were used for 21 LCD- and 43
amiodarone-treated patients. Life expectancy and total variable
costs were predicted with use of a Markov decision analytic model.
Clinical event rates and probabilities were based on published
reports or expert opinion .
Life expectancy with an ICD (6
.1 years) was 50%a greater than
that associated with treatment with amiadarone (3 .9 years) and
2.5 times that associated with conventional treatment (2 .5 years) .
Assuming replacement every 24 months, LCD lifetime treatment
costs (in 1989 dollars) for a 55-year old patient are expected to be
Sudden cardiac death remains the major cause of death in
the United States, with an estimated 400,000 persons af-
fected annually (I) . In the majority of these deaths, the
mechanism is ventricular tachycardia that degenerates to
ventricular fibrillation
. Although approximately 25% of these
patients survive the initial hospital stay without substantial
neurologic impairment (2). the recurrence rate is high : 1-year
mortality rates of 25% to 40% have been reported (3 .4) in
patients who have not had pharmacologic therapy guided by
invasive or noninvasive techniques.
In an attempt to improve treatment efficacy, electrophys-
iologic studies have been used to guide drug therapy: how-
ever, most patients continue to have inducible arrhythmias
From the 'Division of Clinical Decision Making . and ttElectrophy .iology
Service, Division of Cardiology, Department of Medicine . New England
Medical Center and Tuns University School of Medicine . Boston . Massuchu-
seus and the +Division of Cardiology
. Portland Veterans Affairs Medical
Center and the Oregon Health Sciences University. Portland . Oregon . This
study was supported by Training Grant LM 7044 and Research Gram LM 4493
from the Nation) library of Medicine Medical Information Program . Be-
thesds, Maryland . and by a grant from the John A . Hartford Foundation . New
York, New York.
Manuscript received October S. 1990: revised manuscript received No-
vember 4, 1991 . accepted December 19. 1991 .
Address for reurinlg : Greg C. Larsen . 6[D . Cardiology Division I I I.B .
Portland Veterans Affairs Medical Center
. Portland, Oregon 97201 .
401992
by the American College of Cardiology
$89,600 compared with $24,800 for antiodarone and $16,100 for
conventional therapy, yielding a marginal costlefectiveness ratio
for ICD versus amiodarmee therapy of $29,200/year of life saved,
which is comparable to that of other accepted medical treatments .
If technologic improvements extend average battery life to 36
months, the marginal cost/effectiveness ratio would
be $21,8901
year of life saved, and at 96 months it would be $13,S00)year of life
saved . Patient age at implantation did not significantly affect these
results .
If quality of fife on amiodarone therapy is 30% lower than that
with the LCD, the marginal costleffectiveness ratio decreases by
3590 . If the quality of life for patients receiving drugs is 40%
lower than that of patients treated with an ICD, use of the
defibrillator becomes the dominant strategy
.
(J Am Coll Cordial 1992 :19:1323-34)
despite treatment with conventional antiarrhythmic agents
(5-12) and remain at high risk for sudden death. Amiodarone
has been advocated in such patients, with 60% to 90%
remaining free of recurrent clinical events in the year after
initiation of treatment (13-19) .
The implantable cardioverter-defibrillator (ICD) offers an
alternative approach to survivors of out of hospital cardiac
arrest who do not respond to conventional therapy (20) .
However, the costs of the ICD are high. The early devices
cost $13,000, require athoracotomy for initial placement and
must he replaced on average every 18 to 24 months . Fur-
thermore . as the indications for implantation continue to
expand, concern over rapidly escalating health care costs
has beer. focused on new expensive technologies such as the
ICD . Increasingly, proponents of such therapies are asked
whether their benefits can be justified in light of their costs
(21) . Of course, any such evaluation must be in the context
of the costs and benefits of available alternatives .
For this reason, we performed a cost-effectiveness anal-
ysis of the ICD, comparing it both with conventional anti-
arrhythmic drug therapy and with amiodarone therapy in
patients with recurrent sustained ventricular tachycardia or
fibrillation refractory to conventional drug therapy . Our
analysis used actual inpatient and outpatient costs as well as
physician fees generated for patients receiving an LCD or
n735-1017NVS5 .00
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amiodarone therapy for these conditions at a tertiary hospi-
tal between 1985 and 1988. The analysis included an assess-
ment of the impact of future technologic improvements to
battery systems that have already increased the longevity of
the ICD
. We also assessed the extent to which changes in
assumed quality of life with amiodarone therapy (relative to
the ICD) could change the results of our analysis .
Methods
We constructed a Markov or "state transition" decision
model to compare the implantable cardioverter-defibrillator
(ICD), amiodarone and conventional drug therapy in three
cohorts of patients who were assumed to be identical with the
exception of the therapy for their recurrent ventricular arrhyth-
mias . The Markov model assumes that each patient is in one of
a limited array of health states at any point in time and that the
likelihood of that patient moving from one state of health to
another is governed by various fixed and time-dependent
transition probabilities (22) . We used DecisionMaker software
(23) to simulate the prognosis of each cohort and "monitored"
their progress at monthly intervals, tracking relevant events .
total survival time and costs associated with each therapy .
Assumptions . In structuring the decision tree to model
this problem . we made several simplifying assumptions : I)
All patients arc subject to four forces of mortality : a) a
sudden cardiac death rate that is modified by both amio-
darone and the ICD ; b) a nonsudden cardiac death rate.
reflecting variables such as ventricular function ; c) a noncar-
diac death rate, as would affect members of the population at
large ; and d) complications of the ICD or amiodarone . 2) The
case rate for sudden cardiac death is based on patients
treated with conventional therapy whose arrhythmias were
not effectively suppressed during repeat electrophysiologic
testing . 3) There is no crossover between patient groups .
Thus, patients treated with conventional therapy or amio-
darone who survive a recurrence of sudden cardiac arrest do
not receive 1CD implantation . In addition, no crossovers
from the amiodarone group to the ICD group were allowed if
a patient on amiodarone therapy developed an amiodarone
drug reaction
. 4) Equal quality of life is assumed for all
patients with long-term survival ; however, this assumption
was subjected to sensitivity analysis .
The decision model. A complete description of the deci-
sion model is contained in the Appendix . Briefly . there are
three patient cohorts: patients receiving an ICD, amiodarone
orconventional drug therapy (Fig . I). Patients in each cohort
may die during initial hospitalization . If they survive . they
enter the Markov process, where each month they are
exposed to the four forces of mortality described . In addi-
tion, all patients may experience nonlethal cardiac illnesses
(such as exacerbations of heart failure) that require hospi-
talization. All patients are seen routinely for cardiac outpa-
tient visits . Patients on amiodarone therapy may experience
both lethal and nonlethal complications of the drug that may
require hospitalization and discontinuation of amiodarone .
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Patients treated with the ICD may experience complications
associated with the device (for example, infection and lead
failure) that require hospitalization and rpeat operation . In
addition . patients who experience an ICD discharge may
require an outpatient visit or hospitalization . Finally, pa-
tients with an ICD who survive long enough will eventually
require a short hospital stay for ICD battery replacement .
Medical rates and probabilities used in the model . We
reviewed published reports describing therapy and outcomes
for patients treated with an ICD, amiodarone or conven-
tional antiarrhythmic therapy . For probabilities for which no
data were available. the opinions of experienced clinical
electrophysiologists were used . Mortality data from each
study were transformed into an average yearly mortality rate
(24) . Age- and gender-related mortality rates were taken
from U .S . life expectancy tables (25) .
Inpatient costs . Twenty-one patients who underwent ICD
implantation between October 15, 1986 and November 11,
1988 and 43 patients who received amiodarone therapy
between September 18. 1985 and May 20 . 1988 for recurrent
ventricular tachycardia or fibrillation formed the basis of our
estimates of the costs of hospital treatment . All patients
received their initial treatment and follow-up care at the New
England Medical Center .
Each patient's inpatient costs for every admission, in-
cluding those for ICD replacement, were available on the
New England Medical Center's Clinical Cast Manager cost-
accounting system (26), which separates the fixed costs of
each unit of service (including overhead such as heating,
lights and custodial services) from the variable costs of
adding units of similar service (that is, laboratory tests, chest
radiography, nursing care and medications given) (27)
.
Vari-
able costs better reflect the actual costs of care for a specific
condition and were used in this analysis. The costs of
electrophysiologic testing and inpatient medications and the
purchase prices of the ICD generator, intracardiac elec-
trodes and patches were added to patients' variable hospital
costs to produce the final cost total .
htpatieet costs for rite "conventional therapy" group
were derived from those of the amiodarone cohort . We
assumed that their initial and follow-up hospitalization costs
would be similar because they come from the same group
with persistently inducible arrhythmia as did the amio-
darone-treated patients
. However, because they were not
exposed to the risks of amiodarone, they would not be
admitted for amiodarone toxicity .
Outpatient costs . To help ensure complete acquisition of
outpatient costs
. all outpatient services for follow-up clinic
visits were obtained from New England Medical Center's
computer billing records, including office visits, laboratory
services and procedures . Actual variable costs were used for
laboratory tests, chest radiographs, pulmonary function
tests, exercise tolerance tests, electrocardiograms (ECGs)
and Holler monitor recordings . Pharmacy costs for amio-
darone (400 mg/day) were used as an approximation of these
costs for all amiodarone-treated patients . No additional drug
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Figure 1 . Decision model used for
the
cost-effectiveness
analysis. A.
The initial CHOOSE node (solid
square) leads to 0 of the three
therapeutic options (implaetable car-
dioverter-defibrillator [ICD], amio-
deronc therapy [AMID] or conven-
tional a. tiarrhythmic drug therapy
[CONY]). For all three options . if
patients survive the initial hospital
admission . represented by a chance
event node (solid circle))
. they go to
the RHYTHM Markov subtree . B.
The RHYTHM Markov subtree, rep-
resenting the health states in which
patients may exist during each
monthly cycle . M denotes the
Markov node. Oaring each cycle, pa-
tients at solid circles will experience
the risks defined in the PROBLEMS
subtree (C)
.
Patients in the three sur-
gical health states (open circles) expe-
rience PROBLEMS unless they die
at operation . C, The PROBLEMS
subtree . Each terminal branch ends
in a health state listed in the
RHYTHM subtree, to which patients
return to begin the next monthly cy-
cle . Admit = hospital admission :
BATT = battery; CHF = congestive
heart failure; INFXN = infection;
MI = myocardial infarction ; OK =
stable, doing well; OP-CHK = outpa-
tient visit to check patient and ICD ;
RXN = adverse drug reaction ; SCD
= sudden cardiac death .
C
costs were added for any of the patients . Baseline clinic
charges for the "conventional treatment" group were the
same as for the amiodarone group, except the former group
did not incur costs for the laboratory tests, such as lung
diffusing capacity or thyroid function studies performed as
part of surveillance for amiodarone toxicity, nor were they
charged for antiodarone.
CHOOSE
A
LOOSEN COAL
.
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Physician services. Billing records from the New England
Medical Centers medical practice groups were examined to
determine the medical, surgical and anesthesiology charges
billed to and collected from both ICD- and amiodarone-treated
patients for inpatient physician care
. For each patient group,
the average amount billed per patient multiplied by the average
fractional amount actually collected yielded the "recovered
1326
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inpatient physician costs" for physician services for all admis-
sions, including those for generator replacement . This figure
was used to represent inpatient physician costs in our model.
Outpatient billing records were similarly examined to calculate
the average "recovered outpatient physician costs" of office
visits . All inpatient, outpatient and physician costs incurred in
fiscal years 1985 through 1988 have been inflated by 6%/year to
represent all costs in 1989 dollars .
Modeling ICD battery life. We used two models to simu-
late the need for ICD generator replacement . In the simplest
model (model I) . each patient still alive at the end of the
estimated average battery life of his or her ICD received a
replacement battery. In the baseline case, all surviving
patients received a replacement every 24 months. In the
more complex model (model 2), we derived a monthly
battery failure rate based on reported estimates of average
battery "life expectancy" exactly analogous to human life
expectancy (24) . Thus, in model 2, generator replacement
times vary on the basis of a constantly declining exponential
probability of generator survival .
The rate at which ICD batteries require replacement is a
major determinant of the overall cost of treating patients
with an ICD . Battery life for an individual patient is a
function not only of battery technology, but also of fre-
quency of ICD discharges. Thus, battery life will vary as
patient characteristics vary and as energy storage technol-
ogy improves . In the early reports (28-34) on the ICD, the
mean ICD battery life varied from
13 to 22 months . How-
ever, in newer ICD models, the mean battery life has
increased to ?36 months and devices now undergoing
clin-
ical investigation may have nominal longevities of as long as
6 to 8 years. Thus, for our baseline analysis, we used a
conservative estimate of mean battery life of 24
months, but
subjected this variable to sensitivity analysis in which bat-
tery life was varied from 18 to as long as 96 months .
Discounting. Future costs were discounted at 5%/year to
reflect the fact that deferring expenses allows unused resources
to be invested and yield returns before future expenses must be
paid
. Similarly, the benefits derived from treatment (namely,
future years of life saved) were also discounted to reflect the
potential future productivity of these patients and to maintain
internal consistency in our analysis (27,35) .
Quality of life adjustments (utilities)
. In any decision the
ultimate choice is driven by the value attributed to each
possible outcome . Our baseline analysis assumes all survival
to be equally valuable, regardless of treatment received.
Deductions from full life expectancy were made for the
short-term morbidity associated with surgery or hospitaliza-
tion . One week was deducted for elective
ICD generator
replacement. Two weeks were deducted for initial electro-
physiologic testing at the beginning of amiodarone therapy
and for surgery required to implant the ICD, treat a major
postoperative infection or replace defective ICD patches .
We also performed sensitivity analyses in which it was
assumed that quality of life with an ICD was either better or
worse than that on medical therapy .
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Data Summary
Medical Rates and Probabilities in
Reported Studies
Nonsudden cardiac death rate . Table I shows abstracted
data from the largest available studies of patients treated
with conventional therapy, the ICD or amiodarne in which it
is possible to separate sudden and nonsudden cardiac death
rates as well as noncardiac death rates . Among patients treated
with conventional therapy, Wilber et al . (1U reported the
outcome of 166 survivors of sudden cardiac arrest referred for
electrophysiologic studies from 1978 to 1985 (including 10
patients who ultimately received an ICD), and Swerdlow et al .
(10) described their experience with 239 survivors of sudden
cardiac arrest referred for electrophysiologic studies between
1976 and 1982. Among patients treated with the ICD between
1981 and August 1986, Winkle and Thomas (20) summarized
the U .S. experience for 949 patients listed in a central registry.
Other reports describe the experiences of individual institu-
tions (28-30,32) . Some of these patients are probably also listed
in the central registry, so that duplication could not be avoided.
For patients treated with amiodarone, eight studies (13-
15,17,36-40) report on those treated between 1977 and 1985.
Follow-up times are substantially shorter in these reports and
the patients tend to be older than patients in the 1CD- and
conventionally treated groups .
Average yearly nonsudden cardiac mortality rates are quite
variable among studies, but tend to be lower in patients treated
with the ICD and higher in those treated conventionally or with
amiodarone: the weighted average yearly mortality rate for the
ICD group was 5 .54%/year, but was 9
.02%/year for amio-
darone-treated patients and 9 .27%/year for conventionally
treated patients. The reasons for this variation in nonsudden
cardiac death rates are not completely clear . Although patients
receiving the ICD were on average slightly younger than those
treated with amiodarone (weighted mean 58 vs . 60 years old),
left ventricular ejection fraction was similar
. More important,
ICD-treated patients often undergo simultaneous coronary
artery bypass grafting or left ventricular aneurysmectomy,
which may have an independent favorable impact on the
mortality rate from heart failure or myocardial infarction . Also,
ICD treatment is a relatively recent development, paralleling
the increasing use of more aggressive treatments for acute
myocardial infarction, such as thrombolytic therapy and coro-
nary angioplasty
. Patients treated with the ICD may have
received these therapies, bringing with them reductions in the
nonsudden cardiac mortality rate . In addition, selection bias
may have occurred, so that patients with multiple or more
severe noncardiac illnesses (for example, obstructive lung
disease) and a shorter life expectancy were not offered treat-
ment with an lCD .
Yearly sudden cardiac death rates (Table 2). Virtually all
patients selected for amiodarone or ICD therapy
have already
been treated unsuccessfully with conventional anliatrhythmic
drugs guided by serial electrophysiologic testing . Five studies
(5,9-12) provide data from which to calculate yearly survival
1ACC Val . 19. No . 6
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Table l . Reported Yearly Mortality Rates From Nonsudden Cardiac Death
Noo of
	
4-g, EF Yearly Average
PI-Y, of
First Author Pr FlU Age (yrt 11,
Mondity M .-M,
rates for the subgroup of patients treated with conventional
antiarrhythmic agents, whose ventricular arrhythmia remains
inducible at follow-up electrophysiologic testing. Their mortal-
ity rate is quite high (21
.19c/year) . In contrast, the weighted
average yearly mortality rate from eight studies (13,14,16,
17,19,36,38,39) among patients treated with amiodarone is
6.64%/year . For patients treated with the ICD, the mortality
rate is even lower. Winkle and Thomas (20) report a rate of
1 .92%/year; Winkle et al . (32), describing the Stanford experi-
ence between 1981 and 1988, report a rate of 1 .2%/year,
although some of the Stanford patients are probably also fisted
in the central registry report (20) . Manolis et al. (30) recently
reported a mortality rate of 2 .14% . The weighted mean suuden
death mortality rate is thus 1 .82%/year .
Efficacy of andodarone and the ICD for preventing sudden
cardiac death. The sudden cardiac death rate patients whose
ventricular arrhythmia is persistently inducible by electro-
physiologic testing was compared with that of patients
treated with amiodarone or the ICD. Efficacy is defined as
the fractional reduction in the mortality rate, or [(conven-
tional mortality - treated mortality)lconventional mortali-
ty] . Thus, the efficacy of amiodarone is [(21 .14% - 6.64%)1
21 .14%] = 68.6%
. Similarly, the efficacy of the ICD is
[(21 .14% - 1 .82%)/21 .14%] = 91 .4%.
Complications of the IM Worldwide surveillance data
(33) show a 2.99o probability of dying during the index
Cona nt tryat Therapy
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EF = ejection fraction ; FlU = follow-up
; Pt = patients; Pt-yr of mortality = (average yearly mortality) x Ire,
of patients) .
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hospital stay for ICD implantation. Approximately 5% of
patients who are "saved" from sudden cardiac death by an
appropriate ICD discharge will require a hospital admission
and 25% will require outpatient visits, but most will receive
only telephone calls for reassurance . The probability that an
ICD will deliver a clinically inappropriate shock has been
estimated at 3%/month (33,34) . Only 10 of patients who
receive such a shock will require hospital admission, either
for defective hardware or for treatment of newly detected
supraventricular tachycardia . The rate of lead failure has
been reported (20,32,33) to be 2%!year, and the rate ofWD
infection approximately 3%/year.
Complications of amiodarone therapy
. There are varying
reported in-hospital mortality rates during initiation of ami-
odarone therapy. The largest series reported to date
(19),
which reflects the University of California, San Francisco
experience in 462 patients, reports a 5 .4% mortality rate .
Reported studies show that a large number of patients
taking amiodarone have recurrent nonfatal arrhythmia recur-
rences . In fact, only about 20% of amiodarone-treated pa-
tients have a follow-up electrophysiologic study in which
arrhythmia is completely noninducible ; the other 80% have
"modified inducible" or fully inducible arrhythmia (54,37-
40). In addition, recent data from Herre et al . (19) demon-
strate that just over
50% of
all arrhythmia recurrences
among amiodarone-treated patients are nonlethal . Thus,
With ., 111)
Swerdlaw(10)
Total
166 7yr
56 41 0 .072
219 3
yr 56 0 .107
405
Weighted average yearly mortality role = 137-5294051 x 100% = 9,277,.
11.952
25.573
37
.525
Amie4arc
Maaolic(36)
86 18mo 6a 10 0.1776
15 .274
Horowitz (38) 100 131 mo
61 24 0.0873 8 .73
M1Gavcrn (14) 42 In .. 61 30 0.0596
2 .451
Ynoeki(381 54 24 mo 63
29 0.0189 1 .021
Waxman 117) 51 9-
1
0.1669 8.512
Vellri (40) 13 24 mo
59 0.0835 1 .086
Heger(151 45 ISmo 52
0 .0519 1 .886
Nademanee (13) 94 15,o. 56 0 .0516
4.954
Total 487
43.896
Weighted average yearly mortality rate = (43 .9241487) x 100% = 9 .02%
Implaotable nefibrllalor
Manolis (30)
77 3 yr 60 15 00171 1 .317
Winkle (20) 949 4 yr 58 33 0.055
52 .195
Winkle (32) 270 5 yr 58 34 0.0564 15 .228
Kelly (28) 94 4 yr
56 33 0039 3 .(8fi
Mirowski (29) 52
3 9r 56 33 0.144 7488
Total 1,442
79.894
Weighted average yearly mortality Pale = (79 .894/14421 x 100% = 5349
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Table 2 . Reported Yearly Mortality Rates From Sudden Cardiac Death
Yearly
No. of
	
Average Average PJ .yrof
First Author N Age FU EF (701 Mortally Mortality
Abbreviations as
in Table I .
although amiodarone saves lives, it does not always do so by
preventing all arrhythmia recurrences ; rather, it slows the
ventricular tachycardia rate or prevents recurrence of the
worst rhythm
. For these reasons, not all patients for whom
amiodarone was "efficacious" in preventing death can sim-
ply return to the next Markov cycle in the "well" state ;
some require further arrhythmia treatment in the hospital .
Thus, in our baseline analysis, we assume that 50% of the
efficacy of amiodarone in reducing the ventricular arrhyth-
mia mortality rate was due to complete prevention of ar-
rhythmia recurrence . The other 50% of patients were saved
from death because the arrhythmia was modified but not
abolished and they required hospital admission for further
treatment .
The risk of having a drug reaction for which amiodarone
must be discontinued is estimated to be 8 .1%lyear on the
basis of the reported follow-up of 1,013 patients (13-
17,19,36,38-40) . However, the risk of death from amio-
darone toxicity among these patients was small-only four
deaths were directly attributed to amiodarone toxicity
among the 145 patients in whom administration
of the drug
had to be stopped. Thus, we assume that 2 .8% of patients
who experience severe amiodarone side effects will die .
JACC Vol . 19. No . 6
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Costs
Costs used in the model are listed in Table 3.
Inpatient costs . Patients receiving an implantable cardio-
verter-defibrillator in our series had a mean age of 62 years
and a mean left ventricular ejection fraction of 33%. Their
initial hospital stay had a mean duration of 28 days (range 8
1. 52) and the mean length of stay in the intensive care unit
was 3 .3 days (range 1 to 16). Patients treated with amio-
darone had a mean age of 64 years and a mean left ventric-
ular ejection fraction of 31% . Their initial hospital stay had a
mean duration of 30 days (range 8 to 60) and the mean length
of stay in the intensive care unit was 4 days (range 1 to 29) .
Costs for the index hospital stay for both groups of patients
are similar, but total inpatient costs are much higher for the
[CD-treated patients because of the high cost of defibrillator
equipment .
Inpatient physician services
. Records were available for
the initial hospital stay
of all 21 ICD-treated patients. The
average charges billed by surgeons and anesthesiologists for
ICD
implantation were $7,628/patient, of which 61 .5% was
actually collected
. The average medical charges for these
patients were $6,557, of which 60.1% was collected. This
Conventional Therapy
Wilber0 1) 36 56 7 yr 41 0.2849 10 .2564
Swerdlow(10) 102 56 3 yr
37 0.2472 25 .2144
Roy (5) 31 55 1 .5 yr
5 6
0.132 4 .092
Skale (9) 27 52 2 yr 7 60.1371 3 .7017
Kim 112) 27 56 1 .5 yr 38 0.1438 3 .8826
Total
223 47 .1471
Weighted average yearly mortality rate = (47 .14711223) x 100% = 21 .14%
Amiodarone
Manolis (36) 86 64 18 arm 30 0 .0399 3 .4314
Herre(19) 427 61 48 mo 36 0 .0589 25 .1503
Horowitz (38) 100 61 13 mo 24 0 0
McGovern (14) 12 61 10 In, 30 0 .1521 6.3882
Yazeki (39) 54 63 24 me 29 0 .0286 1 .5444
Waxman (171 46 9 mo 0 .1269 5.8374
DiCerlo (161 104 61 16 ma 35 0 .1632 16.9728
Nademanee (13)
96
56 15 ma 0 .0428
4
.1086
Total 955 63.4333
Weighted outrage yearly mortality rate = (63
.4333N55) x 100% = 6.64%
Implantable Defihrillalor
Marolis(30) 77 60 3 yr 35 0.0278 2.1406
Winkle (201
949 58 4 yr 33 0.0192 18.2208
Winkle (32)
270 58
5 yr 34
0
.012
3
.24
Total 1,296 23 .6014
Weighted average yearly mortality rate = (23 .6014)1296) x 100 = 1 .82%
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Table 3
. Costs and Charges Used in the Model
'61.57 collection of charges billed : 160
.17 collection of charges billed .
1787 collection of charges billed : 5669e collection of charges billed.
yielded "recovered inpatient physician costs"- of $4,6911
patient for surgical services and $3 .942 for medical services.
For generator replacement
. recovered costs were $790 .
Inpatient billing records for the amiodarons group were
available for only nine of the most recently treated patients
(admitted from June 12, 1987 to May 20
. 1988) . The average
Table 4
. Baseline Cost/Effectiveness Ratios"
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charges billed by physicians during the index hospital stay
for these patients were $3
.736, of which 66% was actually
collected
. The "recovered inpatient physician costs" for this
group were thus $?466 per patient .
Outpatient costs
. Routine follow-up visits for ICD-
treated patients occurred every 2 months during the 1st year
and then monthly until battery replacement was required .
The clinic charge for each visit is a flat fee, which covers the
costs of F.CGs
. Our patients on amiodarone therapy were
seen on average 5 times/year
. charged an average of $85/
clinic visit and accumulated 8133/visit in variable laboratory
costs
. including costs of pulmonary function tests, chest
radiographs and blood tests
. All such tests were performed
at baseline
. Pulmonary function tests were performed
yearly . Chest radiographs and routine chemistry tests were
then ordered when clinically indicated
. Thyroid function
tests were obtained yearly
. Outpatient billing records for
both groups showed that an averge of 78%c of physician visit
fees was actually recovered .
Results
Baseline Analysis
Using the rates, probabilities and utilities described ear-
lier. the implantable cardioverter-defibrillator
(ICD) is effec-
tive
therapy for patients who have survived sudden cardiac
death (Table 4)- For a 55-year old patient, treatment with the
ICD increases life expectancy over that provided by treat-
ment with amicdarone by >50%Yc (6
.1 vs. 3 .9 years) and over
that anticipated with conventional therapy by almost 15(%
(6.1 vs . 2 .5 years) . Treatment with the (CD
is also costly
.
Given the currently reported 24-month ICD generator re-
placement rate, for a 55-year old patient- the discounted
costs of lifetime treatment with the ICD are almost $87,000
compared with just under $25,000 for treatment with amio-
darone and about $16,000 for conventional treatment
. For
'Using model I and 24-month average battery life
. AMID = amiodamne therapy : CONY = conventional
therapy
: lCD = implantable caedioveder-defihrillalor therapy : LE = life expectancy
: QALY = quality-adjusted life
years .
Therapy
Average LE
IQALYI
Average
Cost 131
Marginal
Gain in LE
(QALY)
Marginal
Cost
Increase IS)
Marginal Cast.
Effectiveness
IS QALY)
Age 45 years
CONY 2
.6 16200
AMID 3
.96 25 .074 1 .36 8,874 6509
ICD
6.43 93,182 247 60 .119 27.561
Age 55 years
CONY 2.54
16
.156
AMID 3.95 24.790
1 .31 4 .634 6.635
ICD 6.07
89.592
2
.22 64 .802 29.244
Age 65 years
CUNV 2
.46 16,071
AMIO 3
.64 24.250 1 .19 8 .179 6.892
ICD
5.46 83.640 1 .82 59 .390 32.674
For Pad,,[,
With an ICD
Index hospital admission
Hospital variable costs
1' 4112
Defibrillator generator
13 .18111
Defibrillator parches Ipairl .510
Defibrillator sensing leads Ipnin 1 .5181
Physieians' recovered costs, surgery' 4,691
Physicians' recovered costs, medical`
3 .942
Generator replacement . hospital admission 1 .079
Generator replacement
. physicians' recovered wsis - 7m
Hospital admission for infcacd implant
17 657
Nonsurpcal repeal hospital admission
'_'111
Annual recovered outpatient physicians cods'
Ist year
46x
After let year
936
For Patients Receiving Amiodarone and Conventional Therapy
index hospi,acxanon
Hospital variable .", nax
Physicians' recovered costs§
2,466
Repeal hospitalization
3 .840
Recovered outpatient physicians costs
. per yearn
15 visitslyrl
33,
For Patients Receiving
.Amiodarane Only
Hospital admission for amiodarone toxicity
4 .810
Monthly pharmacy cost of amindarone 141X) mgtdayl 85
Amiodarone-associated laboratory variable costs per year 665
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this reason, the marginal increase in the cost of anti odarone
compared with conventional therapy required to save I year
of life ($9600) is lower than the marginal cost of the ICD
compared with amiodarone ($29,200) to save I year of life.
Treatment with the ICD is almost as cost-effective for a
65- as for a 45-year old patient (Table 4). Age has such a small
effect on the cost/effectiveness ratio because patients with
recurrent sudden cardiac death die predominantly of their bean
disease and less frequently from other noncardiac illnesses .
Sensitivity Analysis
We performed sensitivity analyses to examine how a
change in one or more of the values used in the baseline case
might influence the outcome of the models .
LCD battery life . Average ICD battery life is a particu-
larly important variable because replacement LCD units are
expensive and represent a large portion of the expected cast
of ICD therapy. Using the simple model (model I I in which
all ratients still alive received a new battery every 24
months, we varied this variable from 18 to 96 months .
anticipating future improvements in battery technology . Not
surprisingly, as battery life increases . the marginal costs of
ICD treatment over those of amiodarone for each year of life
saved decrease sharply (Fig . 2 . model I). If ICD battery life
were 36 months, for example, the marginal costleffective-
ness ratio would be $2I .8001year of life saved : at 60 months
it would be $16,500 and at 96 months it would be $13,800 .
There is no realistic battery life . however, at which treat-
ment with the ICD becomes cheaper than treatment with
amiodarone (Fig . 2) . Thus, therapy with an ICD saves lives,
but involves additional resource costs .
Because costs of ICD treatment are so dependent on
battery life, we used a more complex model of battery life
(model 2) to provide a more refined cost-effectiveness anal-
ysis
. In the second model, we assumed a constant failure
rate, producing an exponentially decreasing battery "surviv-
al" curve . Although the marginal costleffectiveness ratios
for both models agree closely (Fig . 2) . the more complex
model produces slightly higher ratios .
Amiodarone efficacy . The efficacy of amiodarone in pre-
venting mortality from recurrent sudden cardiac arrest was
subjected to sensitivity analysis because reported yearly
mortality rates with amiodarone treatment vary so widely
.
However, amiodarone efficacy would have to decline from
its baseline value of 69% to 15% for its marginal cost/year of
life saved to become higher than that of ICD therapy .
Likewise, we varied the estimated frequency with which
amiodarone protects patients by making a recurrent arrhyth-
mia hemodynamicaily tolerable (as opposed to preventing
the arrhythmia from occurring) because rehospitalization of
these patients could be expected to increase the costs of
amiodarone treatment . However, even Ira- of the efficacy
of amiodarone was due to complete suppression of arrhyth-
mia and all patients treated with this drug required repeat
hospital admission, the marginal cost of the ICD/year
of life
JACC Vol
. 19
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ICD Battery Life (momhs)
Figure 2. Effect of longer implantable cardioverter-defibrillator
)ICD) battery life on marginal costleffectiveness ratio of the ICD
over that of amiodarone therapy . As ICD battery life increases . the
marginal cost of the ICDlyear of life saved decreases significantly
compared with that of amiodarone . Two mathematical models of
battery survival are illustrated . In model 1, all surviving patients
receive a new battery at each multiple of average battery l ife . i n
model 2, batteries fail and are replaced at a constant rate based on
exponentially declining battery "survival" function . Both models
demonstrate similar significant reductions in ICD costleffectiveness
ratios as battery survival increases beyond the assumed baseline
survival of 24 months . The costleffectiveness ratio for amiodamne
compared with that for conventional therapy is shown for compar-
ison.
saved is still almost four times that of amiodarone ($28,900
vs. $7,300) .
Quality of life. Although not formally documented, per-
sonal experience suggests that quality of life with the ICD
may be better than with amiodarone therapy, both because
the ICD is a more effective therapy and thus is reassuring to
patients and because patients with an ICD usually take fewer
cardiac medications and thus experience fewer drug-related
side effects . We therefore progressively reduced the quality
of life with amiodarone therapy from the baseline assump-
tion that it is equal to the quality of life with an LCD (100%)
to the assumption that it results in 10% of the quality of life
achieved with an ICD . In this type of sensitivity analysis,
absolute quantity of life does not change from baseline, only
the relative value
attributed to that quantity . Therefore, total
costs generated by the model do not change from baseline
because they are driven by the absolute quantity of life
derived from each therapy . However, the number of quality-
adjusted life-years derived from amiodarone treatment pre
gressivety declines with each decrement in assumed quality
of life on amiodarone therapy
. As a result, there is a
progressive incremental gain in quality-adjusted life expect
ancy with ICD therapy over that of amiodarone, whereas
JACC Vol. 19, No . 6
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Table S . Quality of Life on Amiodarone
: Influence on Cost-Effectiveness of Implantahle Cardioverter-Defibrillator Therapy
total costs do not change, resulting in a progressive decrease
in the quality-adjusted marginal cost/effectiveness ratio for
ICD therapy . The opposite effect is evident for amiodarone
compared with conventional therapy : as quality of life with
amiodarone therapy decreases, the relative quality-adjusted
cost/year of life on amiodarone therapy increases
.
Baseline quality-adjusted life expectancy with amio-
darone therapy (Table 5) is 3 .9 quality-adjusted life-years but
decreases to 2 .7 quality-adjusted life-years when the quality
of life with drug therapy is only 70% of that with the ICD
. As
a result, the quality-adjusted costleffectiveness ratio of the
lCD compared with amiodarone decreases by 35%, from a
baseline value of $29,200 to $19,200Iquality-adjusted life
year. At the same time, the marginal cost/effectiveness ratio
of amiodarone over conventional therapy increases by 45% .
If the quality of life on drug therapy is <40% of that with an
ICD (boldfaced values, Table 5), the marginal cost/
effectiveness ratio for the ICD becomes less than that for
amiodarone ($14,200 vs . $17,400). The overall value of ICD
therapy then makes amiodarone an illogical choice even if
resources are very limited .
LARSEN ET AL
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'Relative to quality or life with an implantabie cardiovurter.defib llator, Morn CIE
- pal cosuee etiveness ratio: QALE = quality-adjusted life
expectancy : other abbreviations m in Table 4. Values in boldface show the thrvrhold quulily of
liC-un drug Therapy below which the marginal costleffeclivenas
Olio for the ICD is below that for amiodarone .
Alternatively . for some patients, the quality of life with an
ICD may be worse than that with amiodarone therapy
. Some
ICD-treated patients must still take antiarrhythmic drugs,
may have chronic anxiety after receiving shocks while
conscious and alert (occasionally very frequent or inappro-
priate shocks), or have distorted body images after generator
implantation . In such cases, the quality-adjusted cost/
effectiveness ratio for the ICD over amiodarone increases
with each decrease in
IM
quality of life relative to that on
amiodarone therapy (Table 6)
. As the quality of life with an
ICD decreases (relative to that with amiodarone), the qual-
ity-adjusted cost/effectiveness ratio for the ICD increases
from $29,200 to $40,800lyear at 90 quality (an increase of
406
1)
. If the quality of life with an ICD is only 70% of that
with amiodarone, the quality-adjusted cost/effectiveness ra-
tio increases to $193,000/year of quality-adjusted life saved,
an increase of >500%, When the quality of life with an ICD
is <65% of that with amiodarone, [CD quality adjusted life
expectancy drops below that of amiodarone (3 .56 vs 3 .85);
thus, amiodarone therapy dominates the use of an ICD
.
Table 6. Quality of Life With an Implantable Cardioverter-Defibrillator. Influence on Cost-Effectiveness of Implantable Cardioverter-
Defihrillator Therapy
'Relative to quality of life on drugs . D = dominated by amiodarone therapy : iffier abbreviations as in Tables 4 and 5 .
Quality of
Life With
ICD' 1%)
ICD AMID CDNV ICD/AM10 AMIOICONV
Cost
($1
QALE
(QALY)
Cost
IS)
QALE
IQALYI
Cost
(5)
QALE
IQALYI
Marg CIE
15QALY)
Marg CIE
IS QALY)
100 89.592
6 .07 24.790 7 .85
16
.156 2.54 29.244 6,635
90 89,592 5 .44 24,790 3 .85 16,156 2.54 40,770 6.635
80 89,592 4 .82 24.790 3 .85 16,156 2.54 67,291 6.635
70 89.592 4 .19 24.790
3
.85
16,156 2.54
192542
6,635
60 89,592 3 .56 24.790 3 .85 16,156 2.54 D
6,635
50 89,592 2 .94 24,790 3 .85 16,1'6
2 .54
D 6,635
40 89,592
2 .31
24,790 3 .85 16156 2.34 D 6 .635
30 89.592 1 .68 24.790
3 .85
1666
2.54 D
6 .635
20 69,592 1,06 24.790
3 .85 16,156
2.54
D
6,631
10 89,592 0.43 24 .790 3 .85 16,156 2.54 D 6,635
Quality of
Life With
Drugs' (9c)
ICD AMID
CONY ICD'AMIO AMIO :CONV
Cost
IS)
QALE
IQALYI
Cost
IS,
QALE
IQALYI
Coa
ISI
QALE
IQALYI
Matt; CIE
IS QALYI
NLI,x CIE
IS
QALYI
100 89,592 6 .07 24,790 3 .85 16.1% 2 .54
29 .24.1 6635
90 89,592 6 .07 24790 (.46 16.156 2.3
24 .875 7,398
60 89.592 6 .07 21 .790
31(7
16-156
2.04 21 .641 8358
70 89,592 6 .07 24,790
2.69 16 .156 1 .79 19,152 9.604
60 89.592 6.07 24,790 2.3 16 .1(6
1 .53 17.176 11267
50 B9.592 6.07 24,790 1.91 16,136 1 .28
15 .569 13 .686
40 89,592 6.07 24 .790 1.52 16,156 1.02
14,237 17„379
30 89,592 6.07 24 .790 1.13 16,156 0 .77 13
.116 23,802
20 89,592
6.07 24 .790 0 .74 16.156 0,51 122,158 37 .755
10 89,592 6 .07
24,790
0 .26 16-176
0,16 11 .331 91 .252
1 33 2
	
LARSEN ET AL.
COST-EFFECTIVENESS Or THE ICE
Discussion
Life expectancy. Our analysis shows that the implantable
cardiovertcr defbrili .ior (ICD) prolongs life expectancy in
patients who have survived a cardiac arrest from ventricular
tachyarrhythmia and, in particular, life expectancy with the
ICD is >1 .5 times that of patients receiving long-term
treatment with amiodarone . The additional years of life
gained over amiodarone with the use of the ICD require a
resource expense of about $29,200/year of life saved,
whereas the more limited gains of amiodarone over those of
conventional antiarrhythmic drug therapy cost only about
$6,6001additional year gained
. If resources available to treat
such patients were very limited, more survival could be
purchased by giving amiodarone to many patients than by
using an LCD in only a few
.
Cost/effectiveness ratio
. Improvements in battery tech-
nology promise to reduce the marginal costs of the lCD
substantially . If average ICD battery life is extended to 3
years, the marginal cost of the ICD/year of life saved will
decrease
by 25%, if battery life is extended to 5 years, costs
will decrease by >40% and if it is extended to 8 years, costs
will decrease by >50% . Even at currently reported battery
life, the marginal cost-effectiveness of treatment with the
ICD is similar to the marginal cost-effectiveness of directed
clectrophysiologic testing for syncope and bifascicular heart
block and the procedure is much cheaper than empiric
pacemaker insertion for the same condition (41) . Its cost/
effectiveness ratio is comparable to that of coronary bypass
surgery for stable angina pectoris (42) and less than that of
hospital-based kidney dialysis (43). As battery technology
improves, the marginal cost-effectiveness of the ICD will
approach that for treatment of moderate hypertension in
middle-aged men (44) and kidney transplantation for end-
stage renal disease (45).
Quality of life
. In our baseline analysis, we explicitly
avoided ascribing differential values to years of life spent in
different chronic stable states . There are no data on which to
make estimates regarding the differential symptom-free qual-
ity of life with an LCD versus the quality of life obtained by
taking amiodarone or conventional antiarrhythmic agents.
All three strategies require a substantial amount of medical
follow-up (and thus expense and inconvenience) . The psy-
chosocial adjustment of patients, given the uncertainties of
their underlying disease and its treatment, is variable with all
three strategies. Our experience has been that patients
receiving an ICD feel relieved that their problem has been
treated with "state of the art" technology that improves
survival maximally. For those taking no antiarrhyti .mie
drugs, the side effects and inconvenience of pharmacologic
therapy are obviated . Therefore, we performed sensitivity
analyses in which we explored the possibility that quality of
life with amiodarone or conventional drugs may be less titan
that with an ICD. (For technical reasons, we systematically
diminished the estimated quality of life for patients taking
drugs, rather than increasing the quality of life for patients
JACC Vol. 19. Nn. 6
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with an ICD) . We discovered a roughly proportional reduc-
tion in the marginal cost/effectiveness ratio for the ICD over
amiodarne for every decrement in assumed quality of life
on drug therapy. When the quality of life was reduced by
30% compared with that with an ICD, the marginal cost/
effectiveness ratio decreased by 35% . This reduction in
cost/effectiveness ratio is similar in magnitude to that produced
by increasing the mean battery replacement interval from 24 to
42 months. If the quality of life with drug therapy is <40% of
that with an LCD, it becomes cheaper to purchase quality-
adjusted life-years with an ICD than with amiodarone .
Conversely, it may be that for some patients, quality of
life with an lCD is worse than that with amiodarone . If so,
the marginal quality-adjusted costleffectiveness ratio for the
ICD increases rapidly with each decrement in ICD quality of
life relative to that with amiodarone . Thus, if ICD quality of
life is only 90% of that with amiodarone, the marginal
quality-adjusted cost/effectiveness ratio increases by 40%,
and if LCD quality of life decreases to only 70% of that with
amiodarone, the ratio increases by >500% .
Limitations. Our analysis has some limitations . The num-
ber of patients for whom actual costs were obtained is
relatively small . However, these costs, including those for
outpatient follow-up and generator replacement, are actual
variable costs-not estimates-adding strength to the model .
The probabilities of some events in the model (for example,
the likelihood that follow-up for an ICD discharge would
require an outpatient clinic visit or inpatient admission) are
based on expert experience and not reported clinical data .
However, altering these variables in sensitivity analyses had
no significant effect on the overall outcome .
Our analysis does not model crossovers from amiodarone
to ICD therapy, which can
occur
.
In our experience, the
actual proportion of such crossovers is extremely low . We
believed that a strict comparison of the two treatment
strategies would most clearly illustrate the costs and survival
differences between them . However, to test the effect of
crossovers, we modeled a strategy whereby patients receiv-
ing amiodarone who have an amiodarone drug reaction were
treated with an ICD. The results showed only a minimal
increase in the marginal cost/effectiveness ratio of ICD
compared with that of amiodarone therapy ($315 per quality-
adjusted life-year saved), thus not altering the basic Conclu-
sions of our analysis .
Our techniques for modeling the "survival" of an ICD
battery do not fully capture the complexity of actuarial
survival curves for such batteries (34) . We believe, however,
that they adem,ately capture the effects of changing the
battery replacement frequency and its associated expenses .
Comparison with previous studies. The results o,.' our
analysis can be compared with work recently reported by
Knppermano et al. (46), who used 1984 data from large
Medicare databases and collected total charges, not variable
costs, for use in their estimates. They compared LCD treat-
ment with "pharmacologic therapy" not specifically limited
to the most effective drug, amiodarone, and did not compare
JACC Vol. 19 . No. A
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amiodarone with more conventional antiarrhythmic drug
therapy . The pharmacologic therapy group was an amalgam
of patients from presumably applicable Diagnosis-Belated
Group categories ; whether these patients underwent electro-
physiologic testing could not be determined . They assumed
that rates of nonsudden cardiac death were the same for both
LCD- and drug-treated groups . Finally- although they created
a "1991 scenario," they did not perform sensitivity analyses
on expected battery survival of currently implantable systems.
The results of their analysis are also somewhat different
from ours . Their base case cost/effectiveness ratio for the
ICD of $17,100 (in 1986 dollars) of total charges/year of life
saved is still 30% below the $29,200 (in 1989 dollars) of
variable costslyear of life saved in the present analysis after
correction for inflation of medical costs . Furthermore- be-
cause our analysis is based on variable costs rather than
charges, our analysis suggests that the cost/effectiveness
ratio of the ICD is higher than that calculated previously,
perhaps because our analysis compares ICD with amio-
darone therapy, a more effective agent than other pharma-
cologic therapies. Nevertheless, after accounting for meth-
odologic differences, we believe these authors' analysis
generally supports our own .
Conclusions. The current study represents an intensive
evaluation of the cost and outcome of treatment of life-
threatening arrhythmia at one university teaching hospital . It
demonstrates the value of combining traditional data collec-
tion of patient outcome with
clinically
focused data collec-
tion of patient care costs . It illustrates the power of decision
analytic modeling to synthesize these data, along with data
from existing clinical studies. to provide useful analyses of
current medical problems and to assess the potential impact
of future improvements in the treatment of these problems .
Our results show that treatment of survivors of recurrent
sudden cardiac arrest with an ICD substantially increases
life expectancy over that obtained by treatment with amio-
darone and more than doubles life expectancy obtained by
treatment with conventional antiarrhythmic drugs. The mar-
ginal cost-effectiveness of treatment with the lCD versus
amiodarone is highly dependent on the longevity of the ICD
power supply; as battery life improves, cost-effectiveness of
the ICD improves dramatically . In any case, even at present
levels of battery life, the cost-effectiveness of 1CD therapy in
these patients is comparable to that of other accepted medical
treatment., and is not affected substantially by the patient's age .
Appendix
The Decision Model (Fig. 1)
Therapy with the ICD. Patients receiving an implantable cardio-
verter-defibrillator (ICD) may die during their initial hospital stay or
survive, in which case they enter the Markov process in the "ICD
Well" state, Daring each subsequent month they may die of
noncardiac causes, nonsudden cardiac causes (for example, heart
failure or acme myocardial infarction) or complications of the ICD
LARSEN ET AL .
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itself liar example . infection and lead failure) or they may be
exposed to the risk of sudden cardiac death . The latter risk is
reduced by the efficacy of the ICD . Because the ICD is not
completely effective in eliminating death due tea lethal arrhythmia .
there remains a small chance during each momhly cycle that
patients may experience sudden cardiac death
. If sudden death is
aborted h, the LCD, the patient may simply confer with the
physician by telephone, require an outpatient visit or be admitted to
the hospital. Patients whodo not experience any of these events are
still at risk for other complications of heart disease or of the ICD
itself during each monthly cycle
: they tray develop worsening heart
failure or myocardial ischemia, lead failure or infection of the ICD or
the ICD battery may reach its end of life . The latter three events
require hospital admission and surgery. Patients may also experi-
ence a inappropriate ICD discharge, which reflects a rhythm
disturbance other than ventricular lachycardialfibrillaiion . These
problems may also lead to hospital admission .
Patients with an ICD who have no complication during a given
monthly cycle return m the "lCD Well" state to begin the next
cycle. Patients who have a complication requiring
;argery
. may die
at operation or recover, in which case they remain exposed to the
other risks discussed . If they develop a medical problem requiring
hospital admission . they likewise remain exposed to all the risks of
any other patient with an ICD
. If they survive the hospital stay
without other complication. they return to the "ICD Well" state for
the next cycle.
Amiodarone therapy. In contrast, patients on amiodarone ther-
apy enter the Markov process in the "Amio Well" state . During
each monthly cycle they may die of the same age-, gender- and
race-related causes or nonsudden cardiac causes as a patient with an
ICD
. In addition, they are exposed to the same baseline risk of
sudden cardiac death, reduced by the efficacy of amiodarone to
prevent sudden death recurrence . (Some patients for whom am(o-
daeene is effective in preventing death still require hospital admis-
sion because amiodarone often prevents sudden death not by
eliminating ventricular tachycardia
. but by reducing its rate so that
it becomes henrodynamieally tolerable.) Patients who survive these
risks of death, may still require hospital admission for heart failure
or myocardial ischemia or they may have an arniodarone drug
reaction . If so, they may die or survive, but if they survive, they
must stop taking amiodarone and thereby lose its protection against
the baseline risk of sudden cardiac death . They then start the next
cycle in the "Conventional Therapy Well" state, where they remain
exposed to all risks except the risk of an amiodarone drug reaction .
Finally, if they avoid all of the problems mentioned, they begin the
next monthly cycle in the "Amio Well" state .
Conventional therapy. Patients receiving "conventional thera-
py-" by
definition, have persistently inducible ventricular tachyar-
rhythmias at follow-up electrophysiologic study and thus remain
fully exposed to the baseline risk of sudden cardiac death, age- and
gender-related mortality and nonsudden cardiac death . If such
patients do not die during a monthly cycle, they ran a risk of
becoming seek and requiring hospital admission . Otherwise they
return to the "well" state for the next cycle .
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